People: Array Biopharma Inc (ARRY.W)

Summary

Name	Age	Since	Current Position
Kyle Lefkoff	52	2012	Independent Chairman of the Board
Kevin Koch	52	2012	President, Chief Scientific Officer
Ron Squarer	45	2012	Chief Executive Officer, Director
R. Michael Carruthers	55	2002	Chief Financial Officer
David Snitman	60	2012	Chief Operating Officer, Vice President - Business Development
John Moore	48	2002	Vice President, General Counsel, Secretary
Michael Needle	45	2013	Chief Medical Officer
John Zabriskie	73	2012	Lead Independent Director
Gwendolyn Fyfe	60	2012	Independent Director
John Orwin	48	2012	Independent Director
Liam Ratcliffe		2012	Independent Director
Gil Van Lunsen	70	2002	Independent Director

» Insider Trading

Biographies

Name	Description
Kyle Lefkoff	Mr. Kyle A. Lefkoff is Independent Chairman of the Board of Array Biopharma Inc. He has served as the Chairman of the board of Directors since May 1998. From January 2012 through April 2012, Mr. Lefkoff served as interim Executive Chairman following the resignation of former Chief Executive Officer, Mr. Robert E. Conway, in January 2012. When current Chief Executive Officer, Mr. Ron Squarer, was hired in April 2012, Mr. Lefkoff stepped down as Executive Chairman and resumed his position as Chairman of the Board of Directors. Since 1995, Mr. Lefkoff has been a General Partner of Boulder Ventures, Ltd, a venture capital firm and a founding investor in the company. From 1986 until 1995, Mr. Lefkoff was employed by Colorado Venture Management, a venture capital firm. Mr. Lefkoff serves on the board of directors for a number of private companies, including: BaroFold, Inc., miRagen Therapeutics, Trust Company of America, Line Rate Systems and Bioptix Inc. and previously served on the board of directors of publicly-traded ARCA biopharma, Inc.
Kevin Koch	Dr. Kevin Koch, Ph.D., is President, Chief Scientific Officer of Array Biopharma Inc., since May 1998. Prior to forming Array, Dr. Koch was an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams for Amgen Inc. from 1995 to 1998. From 1988 until 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator and Project Coordinator for the cellular migration and immunology project teams. From 1998 to 2003, Dr. Koch was a member of the board of directors of the Inflammation Research Association.
Ron Squarer	Mr. Ron Squarer serves as Chief Executive Officer, Director of Array BioPharma Inc., since April 26, 2012. Prior to Array, Mr. Squarer served as Senior Vice President, Chief Commercial Officer at Hospira Inc., a global pharmaceutical and medical device company, from February 2010 to April 2012, where he was responsible for delivering $4 billion in annual revenue and more than 2,000 employees worldwide. From 2009 to 2010, Mr. Squarer was responsible for strategy, new product development and commercialization, acquisitions, partnerships and portfolio prioritization as Senior Vice President, Global Marketing and Corporate Development and held a similar role focused on Strategy and Business Development from 2007 to 2008. Mr. Squarer joined Hospira from Mayne Pharma, an Australia-based specialty injectable pharmaceutical company, where he served as Senior Vice President, Global Corporate and Business Development from 2006 to 2007 when Mayne was sold to Hospira for $2 billion in 2007. Prior to 2007, Mr. Squarer held senior management roles at both Pfizer, Inc., focused on global oncology commercial development, and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe.
R. Michael Carruthers	Mr. R. Michael Carruthers is Chief Financial Officer of Array Biopharma Inc., since December 1998. He served as Secretary from December 1998 until October 2002. Prior to joining Array, Mr. Carruthers was Chief Financial Officer from October 1993 until December 1998 of Sievers Instrument, Inc. From May 1989 until October 1993, Mr. Carruthers was the treasurer and controller for the Waukesha division of Dover Corporation. Mr. Carruthers was previously employed as an accountant with Coopers & Lybrand, LLP. He currently serves on the Board of Directors of Pyxant Labs, a private company. Mr. Carruthers received a B.S. in accounting from the University of Colorado and an M.B.A. from the University of Chicago.
David Snitman	Dr. David L. Snitman, Ph.D., is Chief Operating Officer, Vice President - Business Development of Array Biopharma Inc. He is no longer Director of the Company effective October 24, 2012. Prior to forming Array, Dr. Snitman held various positions with Amgen Inc. since December 1981, including Associate Director, New Products and Technology and Manager of Amgen's Boulder research facility. Dr. Snitman received a B.S. in Chemistry from Northeastern University and a Ph.D. in the Synthesis of Natural Products from the University of Colorado, and was a National Institutes of Health Postdoctoral Fellow at the Massachusetts Institute of Technology.
John Moore	Mr. John R. Moore is Vice President, General Counsel, Secretary of Array Biopharma Inc., since May 2002. He has served as Vice President and General Counsel since May 2002 and as Secretary since October 2002. Prior to joining Array, Mr. Moore was an associate for three years with the law firm of Wilson Sonsini Goodrich & Rosati where he negotiated transactions involving technology, intellectual property and products. From September 1992 to July 1996, and August 1996 to June 1999, Mr. Moore was an associate with the law firms of Kenyon & Kenyon and Arnold White & Durkee, respectively, where he focused on intellectual property matters.
Michael Needle	Dr. Michael N. Needle, M.D., has been appointed as Chief Medical Officer of Array Biopharma Inc., effective April 1, 2013. He has more than 14 years of pharmaceutical industry experience in drug development and regulatory affairs. He most recently served as the Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF) from April 2012 to March 2013. Prior to his tenure at MMRF, he held multiple Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy from March 2004 to April 2010. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated from April 2000 to February 2004. Dr. Needle did his fellowship in Pediatric Hematology / Oncology at the Children’s Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University.
John Zabriskie	Dr. John L. Zabriskie, Ph.D., is Lead Independent Director of Array Biopharma Inc. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products, Dr. Zabriskie was President and Chief Executive Officer of Pharmacia & Upjohn Inc. (“Upjohn”). As Chairman of the Board and Chief Executive Officer of Upjohn, Dr. Zabriskie led the Upjohn project, which resulted in the $12 billion merger of equals with Pharmacia Corporation. Prior to joining Upjohn in 1994, Dr. Zabriskie was Executive Vice President for Merck & Co., Inc. Dr. Zabriskie currently serves on the Board of Directors of publicly-traded Kellogg Company and ARCA biopharma, Inc. and privately-held Puretech Ventures LLC. He previously served on the Board of Directors of publicly-traded MacroChem Corp. Dr. Zabriskie received a B.S degree in Chemistry from Dartmouth College and his Ph.D. in Organic Chemistry from the University of Rochester.
Gwendolyn Fyfe	Dr. Gwendolyn A. Fyfe, M.D., serves as Independent Director of Array BioPharma Inc., since January 26, 2012. From 1997 to 2009, Dr. Fyfe held various positions with Genentech, Inc. (now a member of the Roche Group), including Vice President, Oncology Development; Vice President, Avastin Franchise Team; as well as the honorary title of Senior Staff Scientist. Dr. Fyfe played an important role in the development of Genentech’s approved oncology agents including Rituxan, Herceptin, Avastin and Tarceva. Dr. Fyfe sat on the development oversight committee for all of Genentech’s products and participated in the Research Review Committee that moved products from research into clinical development. Since leaving Genentech in 2009, Dr. Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies. Dr. Fyfe is a recognized oncology in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. She is a graduate of Washington University School of Medicine and a board certified pediatric oncologist.
John Orwin	Mr. John A. Orwin has been appointed as the Independent Director of Array Biopharma Inc., effective November 6, 2012. Mr. Orwin has served since February 2011 as chief executive officer and a member of the board of directors of Affymax, Inc., a biopharmaceutical company listed on The Nasdaq Stock Market (AFFY). From April 2010 to January 2011, he served as president and chief operating officer of Affymax. From 2005 to 2010, Mr. Orwin served as vice president and then senior vice president, BioOncology Business Unit, at Genentech, where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. From 2001 to 2005, Mr. Orwin served in various executive level positions at Johnson & Johnson overseeing oncology therapeutic commercial and portfolio expansion efforts in the US. He has also held senior marketing and sales positions at Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough Corporation.
Liam Ratcliffe	Dr. Liam Ratcliffe, M.D., Ph.D., serves as Independent Director of Array BioPharma Inc., since April 30, 2012. Dr. Ratcliffe is a General Partner at New Leaf Venture Partners and joined New Leaf in September 2008. Prior to joining New Leaf, Dr. Ratcliffe served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions at Pfizer included Vice President of Exploratory Development for the Mid West region, and Head of Experimental Medicine at Pfizer's Sandwich, UK Laboratories. Dr. Ratcliffe received his M.D. and Ph.D. degrees in immunology from the University of Cape Town and his MBA degree from the University of Michigan. He completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and additional teaching hospitals in Cape Town, South Africa.
Gil Van Lunsen	Mr. Gil J. Van Lunsen is an Independent Director of Array Biopharma Inc., since October 2002. Prior to his retirement in June 2000, Mr. Van Lunsen was a Managing Partner of KPMG LLP and led the firm’s Tulsa, Oklahoma office. During his 33-year career, Mr. Van Lunsen held various positions of increasing responsibility within KPMG and was elected to the partnership in 1977. Mr. Van Lunsen is currently Vice Chairman of the Audit Committee at ONEOK Partners, GP, L.L.C. in Tulsa, Oklahoma. Additionally, Mr. Van Lunsen was the Audit Committee Chairman at Sirenza Microdevices, Inc. and its predecessor entities in Broomfield, Colorado, from July 2002 until December 2007. Mr. Van Lunsen received a B.S./B.A. in Accounting from the University of Denver.

Basic Compensation

Name	Fiscal Year Total
Kyle Lefkoff	205,582
Kevin Koch	845,950
Ron Squarer	2,416,850
R. Michael Carruthers	648,583
David Snitman	730,155
John Moore	671,006
Michael Needle	--
John Zabriskie	--
Gwendolyn Fyfe	--
John Orwin	--
Liam Ratcliffe	--
Gil Van Lunsen	--

As Of 29 Jun 2012

Options Compensation

Name	Options	Value
Kyle Lefkoff	0	0
Kevin Koch	672,277	1,325,884
Ron Squarer	0	0
R. Michael Carruthers	346,082	1,095,177
David Snitman	587,171	1,257,224
John Moore	169,727	238,530
Michael Needle	0	0
John Zabriskie	0	0
Gwendolyn Fyfe	0	0
John Orwin	0	0
Liam Ratcliffe	0	0
Gil Van Lunsen	0	0

Insider Trading

Name	Shares Traded	Price
MOORE JOHN R	20,000	$2.74
MOORE JOHN R	20,000	$6.52
MOORE JOHN R	2,357	$5.69
MOORE JOHN R	26,190	$5.69
SNITMAN DAVID L	16,975	$0.00
SQUARER RON	4,397	$0.00
MOORE JOHN R	11,886	$0.00
CARRUTHERS R MICHAEL	11,391	$0.00
KOCH KEVIN	22,718	$0.00
LEFKOFF KYLE	1,000	$0.00
CARRUTHERS R MICHAEL	1,545	$2.65
CARRUTHERS R MICHAEL	1,994	$2.06
LEFKOFF KYLE	5,415	$0.00
LEFKOFF KYLE	5,415	$0.00
CARRUTHERS R MICHAEL	1,743	$2.35
BVF PARTNERS L P	2,700	$2.14
BVF PARTNERS L P	1,000	$2.14
BVF PARTNERS L P	600	$2.14
BVF PARTNERS L P	7,200	$2.10
BVF PARTNERS L P	20,500	$2.10
BVF PARTNERS L P	4,400	$2.10
BVF PARTNERS L P	17,600	$2.04
BVF PARTNERS L P	56,400	$2.04
BVF PARTNERS L P	9,200	$2.04
BVF PARTNERS L P	15,253	$2.21

» Full list on Insider Trading

People: Array Biopharma Inc (ARRY.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: